A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
NCT06003465 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57
Last updated 2024-03-29
Summary
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.
Conditions
- Healthy
Interventions
- DRUG
-
LY3437943
Administered SC
- DEVICE
-
Test
Used to administer LY3437943 SC
- DEVICE
-
Reference
Used to administer LY3437943 SC
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-08-29
- Primary Completion
- 2024-02-08
- Completion
- 2024-02-08
- FDA Drug
- Yes
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Relative Bioavailability Study of LY3209590 in Healthy Participants
NCT05615532 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3337641 in Healthy Participants
NCT03099148 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of How the Body Absorbs LY3537031
NCT07202871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of LY3039478 in Healthy Participants
NCT02906618 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Two Different Formulations of LY3074828 in Healthy Participants
NCT03188510 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3023414 Formulations and the Effect of Food
NCT02818335 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children
NCT02370485 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
NCT05644353 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3039478 in Healthy Participants
NCT02659865 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
NCT06475729 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants
NCT03220126 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2835219 in Healthy Participants
NCT02327143 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2409021 Formulations and the Effect of Food
NCT01354496 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Two Different Formulations of LY3209590 in Healthy Participants
NCT04768842 ·Status: COMPLETED ·Phase: PHASE1
-
A Relative Bioavailability and Food Effect Study of New Formulations
NCT01398475 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2216684 in Participants With Impaired Hepatic Function
NCT01241435 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
NCT06741657 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3314814 in Participants With Liver Impairment
NCT03499041 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of LY3314814 in Healthy Participants
NCT03222427 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
NCT03617835 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2409021 in Healthy Participants
NCT02217618 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3484356 in Healthy Female Participants
NCT04840888 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3202626 in Healthy Participants
NCT03023826 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
NCT06937619 ·Status: COMPLETED ·Phase: PHASE1
-
Compare Bioavailability of RO7239361 After Subcutaneous Injection
NCT03100630 ·Status: COMPLETED ·Phase: PHASE1